Skip to main content
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED logo

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · MVP ISIN · AU000000MVP2 LEI · 9845007EAECAOD1U4493 ASX Manufacturing
Open in API
Filings indexed 906 across all filing types
Latest filing 2026-05-13 Share Issue/Capital Cha…
Country AU Australia
Listing ASX MVP

About MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

https://medicaldev.com

Medical Developments International Limited specializes in the development and distribution of emergency pain relief and respiratory products. The company's flagship product is Penthrox, a handheld, self-administered inhaler providing rapid-onset, non-opioid analgesia using methoxyflurane. Penthrox is utilized globally by emergency medical services, hospitals, and for procedural pain in various clinical settings. Additionally, the company manufactures a range of respiratory medical devices, including anti-static spacers and asthma management tools designed to optimize medication delivery. The organization focuses on providing portable, effective solutions for acute pain management and respiratory care, catering to healthcare professionals and patients in emergency, surgical, and primary care environments.

Recent filings

Filing Released Lang Actions
Notification of cessation of securities - MVP 4 pages 14.7KB
Share Issue/Capital Change Classification · 85% confidence The document is an ASX Appendix 3H form notifying the cessation (expiry) of performance rights, which is a change in issued capital. It is not a quarterly/annual report, nor a management change, but a regulatory notification of a capital structure change. This fits the “Share Issue/Capital Change” category (SHA).
2026-05-13 English
Appendix 4C and Quarterly Activity Report 31 March 2026 8 pages 401.4KB
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Activity Report' combined with an 'Appendix 4C' (a standard ASX regulatory requirement for quarterly cash flow reporting). It provides comprehensive financial data, including revenue, cash flow statements, and operational updates for the quarter ended 31 March 2026. As it contains substantive financial statements and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q3 2026
2026-04-23 English
Notification of cessation of securities - MVP 4 pages 14.8KB
Share Issue/Capital Change Classification · 82% confidence The document is an ASX Appendix 3H form titled “Notification of cessation of securities,” detailing the expiry and forfeiture of performance rights that have ceased and the resulting issued capital. This is a direct announcement of a change in the company’s issued capital structure rather than an earnings release or management discussion. It therefore falls under a capital change notification. Filing category SHA (“Share Issue/Capital Change”) covers announcements regarding share issues, expiries, lapses or other capital structure changes.
2026-04-19 English
Change in substantial holding 7 pages 186.0KB
Major Shareholding Notification Classification · 90% confidence The document is an Australian Form 604 “Notice of change of interests of substantial holder” under the Corporations Act, detailing prior and current voting power and granular buy/sell transactions by Regal Partners Funds Management. This corresponds to a Major Shareholding Notification (MRQ) rather than a management change, earnings release, or annual report.
2026-04-15 English
FY26 Half Year Report (including Appendix 4D) 23 pages 1.6MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'APPENDIX 4D Half-Year Report' and references the half-year ended 31 December 2025, with comparative data for 31 December 2024. It contains detailed financial data including revenue, EBITDA, EBIT, net profit/loss, cash flow, balance sheet items, segment performance, and outlook commentary. The document also references compliance with ASX listing rule 4.3C.2 and includes a detailed review of operations and financial performance for the half-year period. The length is substantial (15,000 characters) and contains actual financial statements and substantive financial analysis, not just an announcement or summary. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data and analysis. Therefore, the correct classification is IR with high confidence. H1 2026
2026-02-18 English
FY26 Half Year Presentation 17 pages 8.5MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'FY26 HALF YEAR RESULTS' and contains detailed financial data such as revenue, EBIT, NPAT, segment revenues, cash flow, and operational commentary for the first half of fiscal year 2026. It includes comprehensive financial performance metrics, segment analysis, and strategic priorities for the half-year period. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is a full interim financial report rather than a brief announcement or presentation. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2026
2026-02-18 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.